株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の抗高血圧薬市場

Anti-Hypertensive Drugs

発行 Global Industry Analysts, Inc. 商品コード 115503
出版日 ページ情報 英文 893 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界の抗高血圧薬市場 Anti-Hypertensive Drugs
出版日: 2010年02月01日 ページ情報: 英文 893 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の抗高血圧薬市場について分析し、業界の概要、各社の研究開発動向、地域別市場動向、参入企業のプロファイルと競合動向をまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション・調査方法・製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • イントロダクション
    • 高血圧:罹患率
    • 市場概要
    • 現在および将来分析
    • 世界の抗高血圧薬市場をARBが牽引
    • 研究開発における技術革新の欠落とジェネリック化
  • 高血圧:定義、懸念、結果、分類、診断、治療、副作用、主要薬剤
  • 研究開発
    • 武田薬品工業のTAK-536が第3相治験に
    • 中国の医薬品業界がCandesartanジェネリック薬の治験開始
    • Taipei Medical Universityが新たな血圧研究結果を発表
    • 血圧に影響を及ぼす新たな遺伝子研究 他
  • 製品導入
  • 近年の業界活動
  • 世界の主要企業
    • AstraZeneca PLC
    • Bayer AG
    • Biovail Corp.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Ltd.
    • Forest Laboratories, Inc.
    • GlaxoSmithKline PLC
    • Merck & Co., Inc.
    • Mylan, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Ranbaxy Laboratories Limited
    • Sanofi-aventis
    • Solvay Pharmaceuticals SA
    • 武田薬品工業
    • Teva Pharmaceutical Industries Limited
    • The Medicines Company
  • 世界市場見通し

第3章 市場

  • 米国
  • 欧州
  • その他の諸国

第4章 競合環境

目次
Product Code: MCP-6021

Abstract

This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million. The report provides separate comprehensive analytics for US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 145 companies including many key and niche players worldwide such as AstraZeneca PLC, AstraZeneca PLC, Biovail Corp, Biovail Corp, Biovail Corp, Daiichi Sankyo Company, Limited, Dr. Reddy' s Laboratories Ltd., Forest Laboratories, Inc., Forest Laboratories, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG,. Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET AT A GLANCE

  • Introduction
  • Hypertension - Prevalence
  • Market Overview
  • Current and Future Analysis
  • ARBs Lead the World Anti-hypertension Drugs Market
  • Lack of R&D Innovation, Genericization Characterize the Global Anti-Hypertensive Drugs Market

2. HYPERTENSION: Definition, Concerns,

Consequences, Categorization, Diagnosis, Treatment, Side Effects, and Leading Drugs
  • Definition
  • Blood Pressure
  • High Blood Pressure
  • Concerns
  • Consequences
  • Hypertension and Diabetic Population
  • Categorization
  • Primary and Secondary Hypertension
  • Acute Hypertension
  • Diagnosis
  • Treatment
  • Lifestyle Modifications
  • Avoiding Nicotine Products
  • Avoiding Alcohol
  • Avoiding Processed Foods
  • Restricting Sodium
  • Reducing Weight
  • Adopting Biofeedback / Relaxation Techniques
  • Anti-Hypertensive Drugs
  • Beta Blockers
  • Types of Beta-blockers
  • Calcium Channel Blockers
  • Types of Calcium Channel Blockers
  • Angiotensin II Receptor Blockers
  • Types of Angiotensin II Receptor Blockers
  • ACE Inhibitors
  • Types of ACE Inhibitors
  • Diuretics
  • Types of Diuretics
  • Other Anti-hypertensive Drugs
  • Renin Inhibitors
  • Vasodilators
  • Types of Vasodilators and Brand Names
  • Alpha Blockers
  • Mixed Blockers
  • Adrenergic Receptor Agonist
  • Aldosterone Receptor Antagonists
  • Central Alpha Agonists
  • Side Effects
  • Side Effects by Drug Class
  • Thiazide Diuretics
  • Beta-blockers
  • ACE Inhibitors
  • Peripheral Vasodilators
  • Side Effects by Drug Name
  • Side Effects Profile of Select Anti-hypertensive Drugs
  • Select Leading Anti-hypertensive Drugs: A Review
  • Benicar/Olmetec
  • Cleviprex
  • Cozaar
  • Diovan/Diovan HCT
  • Exforge
  • Norvasc
  • Tekturna/Rasilez
  • Tekturna HCT

3. RESEARCH & DEVELOPMENT

  • Takeda' s TAK-536 Reaches Phase III Clinical Trials in Japan
  • China Pharma Commences Clinical Trials for Candesartan Generic
  • Taipei Medical University Reveals Results of New Blood Pressure Study
  • Researchers Identify New Genes Affecting Blood Pressure
  • Italian Study Demonstrates Benefits of Investigational Amlodipine and Telmisartan Combination Treatment in Blood Pressure Patients Exposed to Risk of Cardiovascular Events
  • Gilead Sciences Announces Phase III Darusentan Data
  • Gilead Sciences Commences Phase II Trial of Cicletanine
  • New Clinical Data Demonstrates Effectiveness of Rasilez/ Tekturna in Obese Patients with Hypertension in Comparison to Monotherapy with Diuretic Hydrochlorothiazide
  • New Study Demonstrates Effectiveness of Exforge(r) in Controlling High Blood Pressure in "difficult-to-treat" Patients than Amlodipine Alone
  • New Analyses Demonstrates Use of Cleviprex for Controlling Perioperative Hypertension to Lower the Risk of Heart Attack and Mortality Following Cardiac Surgery
  • Surface Logix Announces Encouraging Phase IIa Results of SLx-2101
  • Observational Study Demonstrates Telmisartan to Provide Powerful Blood Pressure Control for Complete 24-hours, Including the Risky Hours of Early Morning
  • New Study Demonstrates Tekturna(r) When Combined with Diovan(r) to Have Additional Blood Pressure Lowering Effect
  • Protherics Develops High Blood Pressure Vaccine

4. PRODUCT INTRODUCTIONS

  • Takeda Introduces ECARD for Hypertension Treatment
  • Amneal Pharmaceuticals Introduces Benazepril HCI
  • Ranbaxy Laboratories to Introduce Daiichi Sankyo' s Olvance in India
  • Gemini Pharmaceuticals Launches Anti-hypertensive Medicine, Micardis
  • Shionogi Introduces Fluitran(r) 1mg
  • Helvepharm Launches New Anti-hypertensive Drug
  • Ranbaxy Laboratories Introduces Amlodipine
  • Nicholas Piramal Launches Hypertension Management Device
  • GlaxoSmithKline Introduces Ambrisentan
  • Novartis Introduces Aliskiren
  • Dainippon Introduces Avapro for Hypertension Treatment
  • Shionogi Introduces Irbetan for Hypertension Treatment
  • Pfizer Japan Introduces Sildenafil
  • Surgipharm Launches Diovan and Co-diovan
  • King Pharmaceuticals Introduces Altace Tablets
  • Encysive Pharmaceuticals Introduces Thelin Tablets
  • Dr Reddy' s Laboratories Introduces Atocor-R
  • Wockhardt to Introduce Amlodipine Tablets
  • GlaxoSmithKline Launches Coreg CR Extended-Release Capsules
  • Toray and Astellas Introduce Careload LA Tablets
  • Encysive Introduces Sitaxentan Encysive
  • GlaxoSmithKline Introduces Carzec
  • Encysive Pharmaceuticals Introduces Thelin
  • Ranbaxy Laboratories Introduces Generic Drug Verapamil
  • Actavis Group Introduces NIFEdipine (XR) Tablets
  • Apotex Introduces Norvasc Generic
  • Novartis Introduces Aliskiren
  • Encysive Introduces Sitaxentan
  • Pfizer to Release the Generic Version of Norvasc
  • Mylan Introduces Generic Blood Pressure Medicines

5. RECENT INDUSTRY ACTIVITY

  • Sanofi-Aventis Takes Over Helvepharm
  • ARCA Biopharma Merges with Nuvelo
  • Astellas and Nippon Receive Approval for Micombi(r) Antihypertensive Drug
  • The Medicines Co Announces EU Acceptance of MAA for Cleviprex
  • Actelion and GeneraMedix Sign Definitive Agreement
  • AtCor Medical Enters into Contract with Pharmaceutical Company
  • Ranbaxy Receives FDA Approval for Anti-hypertensive Drug
  • Sun Pharmaceuticals Receives Approval for Generic Version of Accupril
  • Sucampo Pharma Americas Wins Rights to Rescula
  • Novartis Obtains Approval from Japanese Health Ministry
  • Novartis Obtains FDA Approval for Exforge HCT
  • Novartis Obtains Approval for Four New Medicines
  • Aveva Drug Delivery Obtains Approval for Clonidine TDS
  • Ranbaxy Receives Approval to Market Anti-Hypertension Drug
  • Actelion Receives FDA Approval for New Ventavis Formulation
  • Sinobiopharma Receives Chinese Approval for Perindopril
  • Pfizer Acquires Encysive Pharmaceuticals
  • GlaxoSmithKline Acquires Bristol Myers Squibb' s Egyptian Business
  • Gilead Sciences Acquires Navitas' Cicletanine Business Assets
  • Shionogi Acquires Sciele Pharma
  • Recordati Acquires Yeni Ilac
  • Kyowa Hakko Merges with Kirin Pharma
  • Belupo and Farmavita Announce Merger
  • Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal
  • Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive Agreement
  • Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb
  • Forest Laboratories Holdings Amends Agreement with Mylan
  • Speedel Secures FDA Approval for Tekturna HCT
  • Lupin Receives FDA Approval for Generic Ramipril Capsules
  • Daiichi Sankyo Submits Application for Anti-hypertensive Drug Approval
  • Mylan Receives FDA Approval for Nisoldipine Extended-Release
  • Glenmark Wins FDA Approval for Trandolapril
  • Novartis Obtains FDA Approval for Tekturna HCT
  • Mylan Receives Tentative Approval for Generic Version of Benicar HCT
  • Novartis Secures Swissmedic Approval for Rasilez HCT
  • Kyowa Secures Japanese Approval for Amlodipine Generic
  • Aurobindo Pharma Obtains FDA Approval
  • Actelion Receives EU Approval for Tracleer
  • The Medicines Company Wins FDA Approval for Cleviprex
  • Indian Pharmaceuticals Wins Approval for Propranolol Hydrochloride Tablets
  • Aurobindo Pharma Secures FDA Approval for Lotensin Generic
  • Zydus Cadila Obtains FDA Approval for Marketing of Benazepril
  • Mylan Wins FDA Approval for Mavik' s Generic
  • Kampala Pharma to Commence Production of High Blood Pressure Drugs
  • Merck Extends Licensing Agreement with AstraZeneca
  • Helpson Receives China FDA Approval to Market Bumetanide Generic
  • Sciele Pharma Obtains FDA Approval
  • DAIICHI SANKYO ILAC Acquires Anti-hypertensive Drug, Concor
  • Novartis' Rasilez HCT Receives European Committee Recommendation
  • Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada
  • Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement
  • Novartis Wins Canadian Approval for Rasilez
  • Hi-Tech Pharmacal Receives ANDA Approval from FDA
  • Dr. Reddy' s Receives FDA Approval for Trandolapril
  • Quantum Genomics and PCAS Pharma Sign Strategic Agreement
  • GeneraMedix Wins Approval from FDA for Epoprostenol
  • Pharmaceutical Holdings Changes Name to URL Pharma
  • Zydus Cadila Obtains Approval from U.S. FDA for Ramipril Capsules
  • Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs
  • KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic
  • Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements
  • Recordati Completes Mutual Recognition with 28 European Nations
  • Recordati Obtains Australian Approval for Zan-Extra(r)
  • Santen Pharmaceutical Obtains Approval for TAPROS
  • Santen Obtains Marketing Authorization for TAFLOTAN
  • Boehringer Ingelheim Wins EU Commission Approval for MicardisPlus(r) 80/25
  • Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR(r)
  • Daiichi Sankyo Establishes Subsidiary in Ireland
  • GlaxoSmithKline Wins EC Marketing Approval for Volibris
  • NicOx Enters into Alliance with Royal DSM
  • NicOx Enters into Alliance with Archimica
  • NicOx Enters into Alliance with Capsugel
  • Novartis Obtains FDA Approval for Exforge and Diovan HCT
  • Actelion and Merck Initiate Phase II Program Dosing, Reach Fourth Milestone
  • Jupiter Bioscience Acquires Drug Technology
  • Recordati- Berlin Chemie Expand Licensing Agreement
  • Meda and Recordati Enter into Agreement for Zaneril(r)
  • Glenmark Wins FDA Approval for Coreg
  • Novartis Secures FDA Approval for Exforge
  • Caraco Receives ANDA Approval for Norvasc Generic
  • Mylan and Forest Labs Win FDA Approval to Market Bystolic
  • Daiichi Sankyo Secures FDA Approval for Azor
  • Teva Bags Approval to Market Accupril Generic
  • Meda and Recordati Sign Long-Term Agreement
  • Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate
  • Caraco Receives FDA Approval for Atenolol Tablets
  • Sciele Pharma and Addrenex Enter into Agreement
  • Novartis Wins Swissmedic Approval for Tekturna
  • Lupin Bags Approval to Market Prinivil' s Generic Version
  • Aurobindo Pharma Receives FDA Approval for Accuretic' s Generic Version
  • Gilead Sciences Wins FDA Approval for Letairis
  • Guangdong Luote Signs Agreement with Nippon Chemiphar
  • Wockhardt Wins FDA Approval to Market Lisinopril
  • Kaken to Commence Marketing Procylin for Pulmonary Hypertension Treatment
  • Encysive Pharma Wins Australian Approval for THELIN(r)
  • Ranbaxy Wins Approval to Market Atenolol
  • Novartis Secures EC Approval for Exforge
  • Ranbaxy Receives Health Canada Approval for Lisinopril Tablets
  • Ranbaxy Receives Tentative Approval for Valsartan Tablets
  • Bristol-Myers and sanofi-aventis Obtain FDA Approval for AVALIDE
  • Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER
  • Ranbaxy Receives Approval from FDA for Coreg Generic
  • KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic
  • Mylan Wins Approval for Propranolol Hydrochloride ER Capsules
  • Novartis Wins EU Approval for Rasilez
  • Actavis Group Secures FDA Approval for Carvedilol Tablets
  • Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets
  • Biovail Reaches Settlement Agreement with Watson Pharmaceuticals
  • Lexicon Genetics Announces Name Change

6. FOCUS ON SELECT MAJOR PLAYERS

  • AstraZeneca PLC (UK)
  • Bayer AG (Germany)
  • Biovail Corp. (Canada)
  • Boehringer Ingelheim GmbH (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Daiichi Sankyo Company, Limited (Japan)
  • Dr. Reddy' s Laboratories Ltd. (India)
  • Forest Laboratories, Inc. (USA)
  • GlaxoSmithKline PLC (UK)
  • Merck & Co., Inc. (USA)
  • Mylan, Inc. (USA)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Ranbaxy Laboratories Limited (India)
  • Sanofi-aventis (France)
  • Solvay Pharmaceuticals SA (Belgium)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceutical Industries Limited (Israel)
  • The Medicines Company (USA)

7. GLOBAL MARKET PERSPECTIVE

  • Table 1: World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 2: World Historic Review Analysis for Anti-hypertensive Drugs by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 3: World 15-Year Perspective for Anti-hypertensive Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Europe and Rest of World Markets for 2003, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. UNITED STATES

  • A. Market Analysis
    • Hypertension - Prevalence
    • Table 4: Hypertension Prevalence Among Adults in the US - Percentage Share Breakdown by Age Group: 2005-2006 (includes corresponding Graph/Chart)
    • Table 5: Hypertension Prevalence Among Adults in the US - Percentage Share Breakdown by Gender: 2005-2006
    • Table 6: Hypertension Prevalence Among Adults in the US - Percentage Share Breakdown by Race/Ethnicity: 2005-2006 (includes corresponding Graph/Chart)
    • Table 7: Hypertension Treatment Among Hypertensive Adults in the US - Percentage Share Breakdown by Gender and Age Group: 2005-2006 (includes corresponding Graph/Chart)
    • Table 8: Hypertension Treatment Among Hypertensive Adults in the US - Percentage Share Breakdown by Race/Ethnicity: 2005-2006 (includes corresponding Graph/Chart)
    • Table 9: Outpatient Department Visit with Hypertension as Co-morbid Chronic Condition in the US - Percentage Share Breakdown by Age Group: 2006 (includes corresponding Graph/Chart)
    • Table 10: Outpatient Department Visits with Hypertension as Co-morbid Chronic Condition in the US - Percentage Share Breakdown by Gender: 2006
    • Market Overview
    • Table 11: US Anti-hypertensive Drugs Market - Sales and Percentage Share Breakdown by Leading Drugs in US$ Million Between October 2007 and October 2008 (includes corresponding Graph/Chart)
    • Table 12: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Class of Drug Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart)
    • Table 13: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of ACE Inhibitors Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart)
    • Table 14: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Angiotension Receptor Blockers (ARBs) Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart)
    • New Patient Therapy Starts to Witness Slowdown
    • Table 15: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Angiotensin II Receptor Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 16: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of ACE Inhibitors by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 17: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Calcium Channel Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart)
    • African Americans At Major Health Risk Due to Hypertension
    • Research & Development
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 18: US Recent Past, Current & Future Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 19: US Historic Review Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2. EUROPE

  • A. Market Analysis
    • Hypertension - Prevalence
    • Non-Invasive Blood Pressure Monitoring on Growth Trajectory
    • Regional Markets at a Glance
    • United Kingdom
    • Hypertension - Prevalence
    • Hypertension Treatment - Monotherapy and Combination Therapies
    • Denmark
    • Cheaper Alternatives for Hypertension Treatment
    • Norway
    • New Branded Drugs Dominate Anti-hypertensive Drugs Market
    • New Amendments to Medicines Reimbursement
    • Proposed New Reimbursement Conditions in Norway
    • Research and Development
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 20: European Recent Past, Current & Future Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 21: European Historic Review Analysis for Anti- hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

3. REST OF WORLD

  • A. Market Analysis
    • Canada
    • Table 22: Canadian Anti-hypertensive Drugs Market - Total Number of Prescriptions in Thousands for 1996 and 2006 (includes corresponding Graph/Chart)
    • Japan
    • Australia
    • Australians to Shell Out More on Anti-Hypertensive Drugs
    • China
    • Hypertension - A Major Health Concern in China
    • Anti-hypertensive Drugs Market
    • Hypertension Outlook
    • Competitive Landscape
    • India
    • Anti-Hypertensive Drugs Manufacturers
    • Korea
    • Anti-hypertensive Drugs Market
    • Table 23: Korean Anti-hypertensive Drugs Market - Leading Classes of Drugs by Value Sales in US$ Million for 2007, 2008, and 2009 (Q1) (includes corresponding Graph/Chart)
    • Table 24: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Drugs by Outpatient Prescription Value for 2007, 2008 and 2009 (H1) (includes corresponding Graph/Chart)
    • Anti-hypertension Drugs Market - Angiotensin Receptor Blockers
    • Table 25: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Angiotension Receptor Blockers by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart)
    • Anti-hypertension Drugs Market - Calcium Channel Blockers
    • Table 26: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Calcium Channel Blocker by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart)
    • Anti-hypertension Drugs Market - Beta-blockers
    • Table 27: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Beta- blockers for 2008 and 2009 (Q1) (includes corresponding Graph/Chart)
    • Kenya
    • Anti-hypertensive Drugs Market
    • Manufacturing Overview
    • Generics Erode Share of Ethical Drugs
    • Research and Development
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 28: Rest of World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
    • Table 29: Rest of World Historic Review Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top